This will have no impact what so ever. Why you ask ? Well here are 2 reasons of the top of my head. 1) Cogstate already has competition and it is used to dealing with it. 2) They are looking to identify digital phenotypes that indicate early indications of Alzheimer it will take at least a decade before they have any useful information. It is only by finding out who goes on to develop AD that they will be able to validate any biomarker as predictive. The results would only be applicable to the Apple ecosystem, the one thing that is becoming very clear with digital biomarkers if you want to meet a clinical levels of proof you need validated consistency across the devices and software used to collect data and then interpret the data. Apple will be able to do this in its ecosystem however results run on say, android, would not be clinically validated.
CGS Price at posting:
$1.06 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)